Wechat official account

 

Headquarters: Building F2, 88 Kechuang, 6th St., Beijing , China
Beijing Office : Suite 2105, Building T2, Dazu Square, Beijing , China
Shanghai Office: 595 North Caoxi Road  Building A Suite 6009 , Shanghai China
Boston Office: 99 Hayden Ave, Lexington, MA 02421, US

Tel: +86  010-56315466

Fax: +86  010-56315314

 

 

Copyright: JACOBIO PHARMACEUTICALS GROUP CO., LTD.   Beijing ICP B 17065868-1   

 

 

关于我们

NEW

NEW

Jacobio Received IND Approval for CD73 mAb JAB-BX102 from FDA

Page view
[Abstract]:
Preclinical data have shown that JAB-BX102 has the advantage of dose activity and has potential to benefit patients with solid tutors.

Jacobio has received IND (Investigational New Drug) approval of CD73 mAb JAB-BX102 from the Food and Drug Administration (FDA) of the United States on Oct 15 2021, Jacobio plans to initiate a Phase I/IIa clinical trial in patients with solid tumors.

JAB-BX102 is Jacobio’s first big molecule program entered into the clinical stage. “The landscape of cancer treatment has been more and more complicated, combination therapies between different modalities are needed. Jacobio’s pipeline focuses on the unmet clinical needs and aims to bring hope to more patients through the in-house combination therapies. As an important IO target, CD73 has the potential to be used in combination with Jacobio's in house SHP2 inhibitors, so as to relieve the immunosuppression of tumor microenvironment, stimulate the proliferation and activation of immune effector cells, enhance tumor immunity and play a synergistic role,” said Dr. Yinxiang Wang, Chairman and CEO of Jacobio.

CD73, also known as ecto -5'- nucleotidase, is a kind of cell surface enzyme, which is widely expressed on the surface of skin cells, lymphocytes, Tregs and other cells. CD73 is a key target in the adenosine pathway, and to date, there has been no approved and marketed CD73 targeted drug globally.

Preclinical data have shown that JAB-BX102 has the advantage of dose activity, it has potential to benefit patients with non-small-cell lung cancer, breast cancer and other solid tutors.

Jacobio has more than ten programs targeting five major tumor pathways including SHP2/RAS, I/O, RB, tumor metabolic and c-MYC, and Jacobio has five drugs targeting SHP2, KRAS G12C, BET and CD73 in the clinical stage.

About Jacobio

Jacobio is committed to providing more products and solutions to people's health. Our mission is to provide compelling innovations for creating a pipeline of life-changing medicines. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. The company's R&D centers are located in Beijing, Shanghai and MA, with a platform and expertise in developing allosteric inhibitors against protein tyrosine phosphatase, KRAS and transcriptional factors.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment, and political, economic, legal and social conditions in China.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.